FAIR VALUE - Narrative (Details)		1 Months Ended	3 Months Ended
	May 20, 2020 USD ($)	May 31, 2020 USD ($)	Jun. 30, 2020 USD ($) $ / shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Short-term contingent consideration				$ 6,776,000	$ 0
Long-term contingent consideration				$ 31,776,000	168,000
Option pricing model | Revenue volatility
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input				0.350
Option pricing model | Discount rate
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input				0.060
Option pricing model | Credit spread
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input				0.059
Collegium warrants
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Proceeds from sale of investments		$ 6,000,000.0
Investment, carrying value derecognized		$ 9,600,000
Loss on sale of investments			$ 3,600,000
Collegium Pharmaceutical Inc | Commercialization Agreement
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Warrant, fair value price (in dollars per share) | $ / shares			$ 16.33
Collegium Pharmaceutical Inc | Commercialization Agreement
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Warrant, expected term			2 years 7 months 9 days
Warrant, risk-free rate			0.27%
Zyla Life Sciences
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration liability				$ 38,400,000
Short-term contingent consideration				6,800,000
Long-term contingent consideration				31,600,000
INDOCIN Products | Zyla Life Sciences | Option pricing model
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, future royalties, estimated revenue, period	10 years
INDOCIN Products | Zyla Life Sciences | Iroko
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent payment consideration, future royalties covenant, product net sales (over)	$ 20,000,000.0
CAMBIA
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration liability				$ 200,000	$ 200,000